Roche Holding AG (RHHVF)
283.49
+2.32
(+0.83%)
USD |
OTCM |
Mar 21, 16:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 226.95B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -26.37% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.463 |
| Price to Book Value | 8.599 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 10.20 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.102 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 31.65% |
News
Headline
Wire
Time (ET)
PR Newswire
12/05 11:00
PR Newswire
05/25 01:00
SA Breaking News
03/02 06:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/02/2024* | 07:00 EST | Earnings Call | Q4 2023 | -- | -- | -- | |
| 07/27/2023 | -- | Results | Q2 2023 | -- | -- | -- | |
| 02/02/2023 | -- | Results | Q4 2022 | -- | -- | -- | |
| 02/02/2023 | 01:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 07/21/2022 | -- | Results | Q2 2022 | -- | -- | -- | |
| 02/03/2022 | 01:00 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 02/03/2022 | -- | Results | Q4 2021 | -- | -- | -- | |
| 07/27/2021 | -- | Results | Q2 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. |
| URL | https://www.roche.com |
| Investor Relations URL | https://www.roche.com/investors.htm |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jul. 27, 2023 |
| Last Earnings Release | Feb. 02, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 16, 2023 |
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 9.637 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 2.566 |
| Yield to Sector | 1.706 |
| Yield to Industry | 0.9098 |
| Last Dividend Amt. | 10.20 |
| Dividend Frequency | Annually |
| Last Ex-Dividend Date | Mar. 16, 2023 |
| Yield (TTM) | 3.60% |
| Forward Yield | 3.59% |
| Payout Ratio | 49.82% |
| Cash Payout Ratio | 40.74% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 21, 2023.
Fundamentals
| Revenue (TTM) | 68.27B |
| Total Expenses (TTM) | 47.55B |
| Net Income (TTM) | 15.49B |
| Total Assets (Quarterly) | 90.88B |
| Total Liabilities (Quarterly) | 60.55B |
| Shareholders Equity (Quarterly) | 26.39B |
| Cash from Operations (TTM) | 23.70B |
| Cash from Investing (TTM) | -5.629B |
| Cash from Financing (TTM) | -18.19B |
Ratings
Profile
Edit
| Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. |
| URL | https://www.roche.com |
| Investor Relations URL | https://www.roche.com/investors.htm |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jul. 27, 2023 |
| Last Earnings Release | Feb. 02, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 16, 2023 |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| MGRBX | 562.76M CHF | 4.19% |
| FIGSX | 495.38M CHF | 3.61% |
| MRIBX | 430.74M CHF | 2.87% |
| VGK | 414.22M CHF | 1.84% |
| FSPSX | 551.76M CHF | 1.38% |
| EFA | 622.66M CHF | 1.35% |
| IEFA | 1.053B CHF | 1.16% |
| VDVIX | 1.528B CHF | 0.96% |
| VEA | 1.528B CHF | 0.96% |
| VEU | 407.60M CHF | 0.84% |
| VTISX | 2.636B CHF | 0.72% |
| VXUS | 2.636B CHF | 0.72% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| RHHVF Tweets |